Profitability
Weight: 25%
D
37
- 5yr Avg ROIC 0.1%
- Operating Margin Trend +128.94 pp/yr
KRYS
Krystal Biotech, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 2 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
12
- 5yr Avg ROE 1.6%
- 5yr Share-Count CAGR 7.8%
Growth Quality
Weight: 25%
A
88
- 5yr Revenue CAGR 177.0%
- 5yr EPS CAGR 318.8%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -36.3%
- 5yr FCF/NI Conversion -2.31x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -4.18x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 56.80
Stability
Weight: 5%
D+
42
- EPS Volatility (σ/μ) 0.95
- Piotroski F-Score 5
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 3 added.
- Holders
- 3
- Avg Δ position
- +236.8%
- New buys
- 0
- Full exits
- 0
- Dalio increased +363%
- Cooperman increased +346%
- Greenblatt increased +2%